Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Childhood immunisation today

J Eskola1

  • 1National Public Health Institute, Helsinki, Finland. j.eskola@ic.ac.uk

Drugs
|June 9, 1998
PubMed
Summary

New vaccine development is advancing due to better knowledge of pathogenesis and biotechnology. However, widespread use requires time, public information, and economic analyses for rational policy decisions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical findings in relation to mortality in non-tuberculous mycobacterial infections: patients with Mycobacterium avium complex have better survival than patients with other mycobacteria.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2015
Same author

Surveillance of influenza in Finland during the 2009 pandemic, 10 May 2009 to 8 March 2010.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2011
Same author

Foresight in medicine: current challenges with Haemophilus influenzae type b conjugate vaccines.

Journal of internal medicine·2010
Same author

The second Geneva Consensus: Recommendations for novel live TB vaccines.

Vaccine·2010
Same author

A TL-based anthropomorphic benchmark for verifying 3-D dose distributions from external electron beams calculated by radiotherapy treatment planning systems.

Radiation protection dosimetry·2006
Same author

[Do vaccines cause allergy?].

Duodecim; laaketieteellinen aikakauskirja·2002

Area of Science:

  • Immunology
  • Biotechnology
  • Public Health

Background:

  • Advances in understanding infection pathogenesis and host responses, coupled with biotechnology progress, are driving new vaccine development.
  • Despite promising vaccine candidates, a significant time lag exists between laboratory development and practical application.
  • New vaccines like acellular pertussis and rotavirus are being introduced, with others like varicella, inactivated polio, and hepatitis B vaccines proposed for optimized use.

Purpose of the Study:

  • To highlight the progress and challenges in new vaccine development and implementation.
  • To emphasize the importance of public information and economic evaluations in vaccine policy.
  • To advocate for a rational policy framework for the adoption of novel vaccines.

Main Methods:

  • Review of current trends in vaccine development and introduction.
  • Analysis of factors influencing vaccine uptake and coverage.
  • Discussion of economic evaluation methods for new vaccines.

Main Results:

  • Several new vaccines are nearing or undergoing introduction.
  • Significant delays are common between vaccine discovery and public availability.
  • Economic analyses (cost-benefit, cost-effectiveness, cost-utility) are crucial for informed decision-making.

Conclusions:

  • While progress in vaccine science is rapid, practical implementation requires careful consideration of timelines and public engagement.
  • Effective communication regarding vaccine properties and usage is essential for maintaining high vaccination coverage.
  • Economic analyses provide a necessary foundation for establishing rational and evidence-based vaccination policies.

Related Experiment Videos